Its therapeutic activity against HER2+ breast carcinoma is being evaluated in phase II trials, but also some authors such as Li et al. [101] and Jiang et al. [5] have showed its efficacy as a targeted therapy for HER2+ gastric and ovarian cancers, respectively. Here, ERBB2 is linked to breast carcinoma.